eClinical Solutions LLC, a leading global provider of cloud-based products for clinical research and software driven clinical data services, announced that Celsius Therapeutics has selected the elluminate clinical data platform for use in their research programs. elluminate is used by Life Sciences companies to aggregate, standardize and analyze data from numerous systems and sources across trials, providing clinical teams with rapid data insights, improved data quality and reduced cycle times.
Celsius Therapeutics is developing a new model of target and drug discovery that leverages a systematic approach to single-cell sequencing. A key component of their strategy is building a database of single-cell genomic and patient clinical information to discover precision medicines for patients with autoimmune diseases and cancer, and other complex diseases. Celsius is using the elluminate platform and Mapper application to:
-
Aggregate clinical metadata within and across studies, without the time and costs associated with relying on programmers to aggregate and standardize data
-
Integrate numerous different and disparate data sources for rapid clinical and translational insights
“We are inspired by the work of clients like Celsius Therapeutics who are taking innovative approaches to the discovery of new medicines,” said Raj Indupuri, eClinical Solutions Co-Founder and CEO. “The elluminate platform and Mapper application are designed to help life sciences companies like Celsius unlock the value of their data faster, replacing manual processes with automated insights.”
About eClinical Solutions LLC
eClinical Solutions is a leading provider of cloud based enterprise software and software-driven clinical data services. The elluminate® platform provides life sciences companies with greater control of their clinical trial data. elluminate software and data driven services have been used by more than 100 life sciences companies on more than 500 trials. For more information, visit www.eclinicalsol.com.
About Celsius Therapeutics
Celsius Therapeutics is charting a new course of target and drug discovery by applying a systematic approach to single-cell sequencing of patient tissue, combining massive datasets, complex algorithms, and machine learning to discover first-in-class precision therapies with a transformative impact on the lives of patients with autoimmune diseases and cancer. Celsius was launched in 2018 and is based in Cambridge, Mass. For more information, please visit www.celsiustx.com.